Walleye Capital
REGN icon

Walleye Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Walleye Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$62.4K Sell
100
-1,100
-92% -$749K ﹤0.01% 4097
2026
Q1 		$927K Sell
1,200
-2,600
-68% -$1.99M ﹤0.01% 2140
2025
Q4 		$2.93M Buy
3,800
+100
+3% +$67.9K 0.01% 1552
2025
Q3 		$2.08M Sell
3,700
-4,700
-56% -$2.66M 0.01% 1552
2025
Q2 		$4.41M Buy
8,400
+2,300
+38% +$1.28M 0.02% 945
2025
Q1 		$3.87M Sell
6,100
-2,100
-26% -$1.44M 0.02% 958
2024
Q4 		$5.84M Buy
8,200
+100
+1% +$83.9K 0.01% 973
2024
Q3 		$8.52M Hold
8,100
– – 0.02% 797
2024
Q2 		$8.51M Sell
8,100
-6,000
-43% -$5.82M 0.02% 879
2024
Q1 		$13.6M Buy
14,100
+10,800
+327% +$10.3M 0.02% 636
2023
Q4 		$2.9M Sell
3,300
-6,500
-66% -$5.35M 0.01% 1502
2023
Q3 		$8.07M Buy
9,800
+3,300
+51% +$2.59M 0.02% 696
2023
Q2 		$4.67M Buy
6,500
+100
+2% +$77.1K 0.02% 770
2023
Q1 		$5.26M Buy
6,400
+6,100
+2,033% +$4.6M 0.08% 309
2022
Q4 		$216K Hold
300
– – ﹤0.01% 1985
2022
Q3 		$207K Buy
+300
New +$189K ﹤0.01% 2090
2020
Q1 		– Sell
-4,500
Closed -$1.69M – 1520
2019
Q4 		$1.69M Sell
4,500
-30,900
-87% -$10.4M 0.11% 253
2019
Q3 		$9.82M Buy
35,400
+24,400
+222% +$7.22M 0.58% 14
2019
Q2 		$3.44M Buy
11,000
+4,500
+69% +$1.5M 0.38% 28
2019
Q1 		$2.67M Buy
+6,500
New +$2.68M 0.44% 7

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Walleye Capital's REGN Position: Q2 2026 in Review

Walleye Capital increased its Regeneron Pharmaceuticals (REGN) stake by 462% in Q2 2026, buying an estimated $12.6M and bringing the position to 22,596 shares worth $14.1M. The position accounts for 0.05% of the portfolio, ranked #358.

Walleye Capital first reported a position in REGN in Q1 2019 and has held it in 20 quarters since. The position peaked at $49.2M in Q3 2025. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Walleye Capital held 22,596 shares of Regeneron Pharmaceuticals worth $14.1M as of Q2 2026.
  • Walleye Capital bought 18,574 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $12.6M.
  • Regeneron Pharmaceuticals made up 0.05% of Walleye Capital's portfolio in Q2 2026, its #358 holding.
  • Walleye Capital first reported a position in Regeneron Pharmaceuticals in Q1 2019 and has held it in 20 quarters since.
  • Walleye Capital's Regeneron Pharmaceuticals position peaked at $49.2M in Q3 2025.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.